Publications

Randel Richner

(abbreviated list)

Richner R, Tuden D. Will CREST Save CAS? Endovascular Today. 2011 September; p.65-70.
Leighton JA MD, Gralnek IM MD, Richner R, Lacey MJ, Papatheofanis FJ MD. Capsule Endoscopy in Suspected Small Bowel Chrohn’s Disease: Economic Impact of Disease Diagnosis and Treatment. Mayo Clinic. 2009.
Beusterien K, Leidy N, Sullivan E, Richner R, Muni NI. Integrating the patient’s perspective into device evaluation trials. Value Health. 2006 Nov-Dec.
Halpern MT, Schmier JK, Richner R, Guo C, Togias A. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma. 2004 Feb;41(1):117-26.
Richner R. A proactive approach to reimbursement in the era of drug-eluting stents. J Cardiovasc Manag. 2002 Sep-Oct;13(5):32-3.
Vera-Llonch M, Menzin J, Richner RE, Oster G. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother. 2001 Jul-Aug;35(7-8):846-51.
Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001 May;37(6):1692-9.
Menzin J, Huse DM, Richner R, Oster G. Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumonia. Pharmacoeconomics. 1992 Aug;2(2):171-7.
Picard VT, Sayers MH, Spinowitz BS, Richner RE. Transfusion therapy: associated risks and alternative approaches. ANNA J. 1990 Dec;17(6):457-64.
Deniston OL, Luscombe FA, Buesching DP, Richner RE, Spinowitz BS. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. ASAIO Trans. 1990 Jul-Sep;36(3):M157-60. http://www.ncbi.nlm.nih.gov/pubmed/2123632

Dan Tuden

(abbreviated list)

“Neuroendovascular Diseases: Past, Present and Future” Daniel Tuden and Joseph Fitzgerald in Controversies in Neurological Surgery, Lawton, M.T; Gress, D.R.; Higishida, R.T. Thieme Medical Publishers, Inc. 2006.
“Mortality Following Subarachnoid Hemorrhage Varies with Hospital Case Volume in 18 State Analysis”- Journal of Neurosurgery, November 2003, Cross, Tirschwell, Clark, Tuden, Derdeyn, Moran and Dacey.
Daniel Tuden, “State HMO Grievance Report– Something to Complain About?” California Physician Magazine, September 1997.
William Pease, James Robinson and Daniel Tuden, “Taxing Pesticides to Fund Environmental Protection and Integrated Pest Management,” California Policy Seminar, January 1996.
US General Accounting Office, GAO/RCED-94-90: SUPERFUND: “Further EPA Management Action is Needed to Reduce Legal Costs.”
Daniel Tuden, Dissertation Title: “The Devil is in the Details: Why Government Contracting Cannot Work Like the Private Sector”. University of California, Berkeley, California, 1995.

Mary Ann Clark

(abbreviated list)

Hornberger J, Kumar K, Clark MA, Hernandez J, Verhultz E. Rechargeable spinal cord stimulation systems versus nonrechargeable systems for patient with failed back surgery syndrome: a cost-consequences analysis. The Clinical J Pain 2008 Mar-Apr;24(3): 244-52.
Bakhai A, Stone G, Mahoney E,…, Clark MA, et al. Cost-Effectiveness of paclitaxeleluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:253-61.
Clark MA, Bakhai A, Pelletier EM, Cohen DJ. Clinical and economic effects of coronary restenosis after percutaneous coronary intervention in a managed care population. Managed Care. 2005;April:42-51.
Pelletier EM, Hernandez J, Clark MA, et al. Medicare costs and health resource utilisation associated with atrial fibrillation in the elderly. Journal of Medical Economics. 2005;8:55-65.
Halpern MT, Lacey M, Clark MA, Valentin MA. Changing treatment patterns for coronary artery revascularization in Canada: the projected impact of drug eluting stents. BMC Cardiovascular Disorders. 2004;4:23.
Clark MA, Bakhai A, Lacey MJ, Pelletier EM, Cohen DJ. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of Medicare claims data. Circulation. 2004;110:259-264.
Hodgson JM, Bottner RK, Klein LW, …Clark MA. Drug-eluting stent task force: final report and recommendations of the working committees on costeffectiveness/economics, access to care, and medicolegal issues. Catheterization and Cardiovascular Interventions. 2004;62:1-17.
Cross DT, Tirschwell DL, Clark MA, Tuden D, Derdeyn CP, Moran CJ, Dacey RG. Mortality rates after subarachnoid hemorrhage: variations according to hospital case volume in 18 states, The Journal of Neurosurgery, Volume 99, November 2003, pp. 810-817.
Motheral B, Brooks J, Clark MA, Crown B, Davey P, Hutchins D, Martin B, Stang P. A checklist for retrospective database studies – report of the ISPOR task force on retrospective databases. Value in Health 2003;2:90-97.
Subramanian S, Clark MA, Isaacson K. Outcome and resource use associated with myomectomy. Obstetrics & Gynecology. 2001;98:583-587.
Leape, L, Clark(Freshour), et.al. Small group judgment methods for determining resource-based relative values. Medical Care. November 1992 supplement.